Momenta Pharmaceuticals Inc (MNTA)

14.15
0.35 2.54
NASDAQ : Health Care
Prev Close 13.80
Open 13.90
Day Low/High 13.50 / 14.60
52 Wk Low/High 7.86 / 23.62
Volume 518.78K
Avg Volume 556.10K
Exchange NASDAQ
Shares Outstanding 71.02M
Market Cap 1.00B
EPS -1.30
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Momenta Pharmaceuticals Announces Publication On The Design Of M230, A Novel Autoimmune Disease Drug Candidate, In Science Translational Medicine

Momenta Pharmaceuticals Announces Publication On The Design Of M230, A Novel Autoimmune Disease Drug Candidate, In Science Translational Medicine

Data show M230's ability to block immune complex-mediated damage and robust efficacy in preclinical

Momenta And Mylan Initiate Phase 1 Clinical Trial For M834, A Proposed Biosimilar Of ORENCIA® (abatacept)

Momenta And Mylan Initiate Phase 1 Clinical Trial For M834, A Proposed Biosimilar Of ORENCIA® (abatacept)

-- Advancement of M834 to clinical-stage development represents important milestone in the Momenta/Mylan biosimilar portfolio --

Momenta And Mylan Initiate Phase 1 Clinical Trial For M834, A Proposed Biosimilar Of ORENCIA® (abatacept)

Momenta And Mylan Initiate Phase 1 Clinical Trial For M834, A Proposed Biosimilar Of ORENCIA® (abatacept)

Advancement of M834 to clinical-stage development represents important milestone in the Momenta/Mylan biosimilar portfolio

Momenta Pharmaceuticals (MNTA) Stock Surges, Barclays Upgrades

Momenta Pharmaceuticals (MNTA) Stock Surges, Barclays Upgrades

Momenta Pharmaceuticals' (MNTA) stock rating was raised to 'overweight' at Barclays on Tuesday.

Momenta, Coherus BioSciences Are Both Good Options in the Biosimilar Space

Momenta, Coherus BioSciences Are Both Good Options in the Biosimilar Space

Momenta may be a good option for value-oriented investors, while Coherus may be better for those who prefer a company that is likely to gain momentum.

Momenta Pharmaceuticals To Regain Global Development And Commercialization Rights To M923, A Proposed Biosimilar Of HUMIRA® (adalimumab), Through Termination Of Collaboration Agreement With Baxalta, Now Part Of Shire

Momenta Pharmaceuticals To Regain Global Development And Commercialization Rights To M923, A Proposed Biosimilar Of HUMIRA® (adalimumab), Through Termination Of Collaboration Agreement With Baxalta, Now Part Of Shire

Shire to continue to fund the M923 program for twelve months and will transfer all remaining clinical, regulatory and commercialization activities to Momenta

First Week of November 18th Options Trading For Momenta Pharmaceuticals (MNTA)

First Week of November 18th Options Trading For Momenta Pharmaceuticals (MNTA)

Investors in Momenta Pharmaceuticals Inc saw new options begin trading this week, for the November 18th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the MNTA options chain for the new November 18th contracts and identified one put and one call contract of particular interest.

Shark Bites: Energous, NeoPhotonics Top My Watch List

Shark Bites: Energous, NeoPhotonics Top My Watch List

The market action is solid today as my hunt for individual stock picks continues.

Bullish Two Hundred Day Moving Average Cross - MNTA

Bullish Two Hundred Day Moving Average Cross - MNTA

In trading on Friday, shares of Momenta Pharmaceuticals Inc crossed above their 200 day moving average of $12.28, changing hands as high as $12.83 per share. Momenta Pharmaceuticals Inc shares are currently trading up about 14.4% on the day.

Visium Hedge Fund Partner Charged in Insider Trading Case

Visium Hedge Fund Partner Charged in Insider Trading Case

After a Supreme Court setback to the federal crackdown on insider trading, U.S. Attorney Preet Bharara signals his intent to forge ahead with new indictments reminiscent of the SAC case.

Momenta Pharmaceuticals Announces Presentation Of Final Data From Phase 1 Trial Of Necuparanib In Patients With Pancreatic Cancer At ASCO

Momenta Pharmaceuticals Announces Presentation Of Final Data From Phase 1 Trial Of Necuparanib In Patients With Pancreatic Cancer At ASCO

Novel oncology candidate necuparanib had favorable tolerability and encouraging signals of activity in Phase 1 study

Insider Trading Alert - STS, RRGB And MNTA Traded By Insiders

Insider Trading Alert - STS, RRGB And MNTA Traded By Insiders

Stocks with insider trader activity include STS, RRGB and MNTA